Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study.
about
2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiativeDefinition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus.Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.Autoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly.EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT).A disease activity score for polymyalgia rheumatica.Best practice in primary care pathology: review 2Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the managementInterleukin-1 and neuronal injury.Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy.Vascular endothelial growth factor levels and rheumatic diseases of the elderly.Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica."In sickness and in health": the peculiar occurrence of polymyalgia rheumatica in married cohabiting couples--a case series and review of the literature.Polymyalgia rheumatica: 125 years of progress?Polymyalgia rheumatica: 125 years of epidemiological progress?Recent advances in polymyalgia rheumatica.Recent advances in the diagnosis and treatment of polymyalgia rheumatica.The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease.Reducing inappropriate ESR testing with computerized clinical decision supportAtypical giant cell arteritis presenting as lack of a pulse in the upper extremity.Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study.Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR).Determination of the length of sedimentation reaction (erythrocyte sedimentation rate) in non-anticoagulated blood with the Microtest 1.Remediable hyperglycaemia in a patient with polymyalgia rheumatica.Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable.Erythrocyte sedimentation rate measurement by VES Matic Cube 80 in relation to inflammation plasma proteins.[Polymyalgia rheumatica in daily routine practice].[Autoimmune rheumatic diseases: from symptom to diagnosis].Polymyalgia rheumatica with normal values of both erythrocyte sedimentation rate and C-reactive protein concentration at the time of diagnosis: a four-point guidance.
P2860
Q28081356-0355CB56-21F9-49B6-A9C4-8D44D83B8638Q33753599-D9637476-E9C4-4D48-9C8F-6081693AEBC8Q34205665-F2DEF453-71EC-4DF0-B40F-F8C9B98F9A5DQ34493588-1077304B-3343-4FCF-A36A-51DD4B693EB7Q35135284-446D0C9A-D353-481A-8E07-D4239CD0A8FDQ35552286-1086A2FE-6EBD-4B7B-8634-D262B8D39B2DQ35553332-59CD7B42-51A5-455A-A99B-94A3BA1F4163Q35769740-5A85E97F-E594-431A-A646-EC27115AE709Q35770303-72ED8BA2-4700-46BD-B0FC-8464469886A7Q36202191-0A333F81-07FC-43FE-AED9-97B10C50D702Q36834474-9080C2A4-8CB2-4F93-9262-4F064FF7E885Q37465216-28C3CBDE-6FCB-4EA5-B4D6-33238296C367Q37498527-B93583D9-D07C-4FFC-B3CE-A9EF0466781EQ38204295-2BF225CC-339D-4ACE-976B-15EB8D1C46B5Q38247259-C92B580F-D13D-4E42-9B9F-A5C61FF47A75Q38247260-7C868C0D-F6FB-4904-97A2-4774DA914F75Q38513257-2BB903A1-F5D2-4813-B637-72377F25ED33Q38808560-86603724-0F1C-4C33-964E-9347587CF7BAQ38915556-9375E796-5F4B-4B79-B4D5-EC7E4BF537B5Q39898448-F416C10F-2DA4-4AFF-8720-C72F68797D33Q41201425-9A453E6B-A9A5-4A25-B72A-A906581F09E2Q43197430-EFF561F6-8DDD-426F-93AD-E5304820B4A6Q43548077-C6440668-2C93-45E1-B6BE-6A22790E36B5Q44144754-F649DABA-A108-4423-A59B-3CBE32E8DCF3Q46879922-F47FB707-28C2-441B-879B-8EDFDA9A858FQ49963991-BBE153B0-57A4-49B3-824D-28816407C3BAQ51569504-47E6E0B3-F671-49C5-803E-5BDE889BE8B3Q52876266-E7ED25C2-E204-4E82-8820-51DE326A1979Q54748524-BC256F9C-3C66-4DF2-9F45-106774BF0830Q55082878-F4F522CD-1443-42F4-966A-FE2177BC94D1
P2860
Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Erythrocyte sedimentation rate ...... a prospective follow-up study.
@ast
Erythrocyte sedimentation rate ...... a prospective follow-up study.
@en
type
label
Erythrocyte sedimentation rate ...... a prospective follow-up study.
@ast
Erythrocyte sedimentation rate ...... a prospective follow-up study.
@en
prefLabel
Erythrocyte sedimentation rate ...... a prospective follow-up study.
@ast
Erythrocyte sedimentation rate ...... a prospective follow-up study.
@en
P2093
P356
P1476
Erythrocyte sedimentation rate ...... a prospective follow-up study.
@en
P2093
Macchioni L
Olivieri I
Salvarani C
P356
10.1053/SARH.2000.8366
P577
2000-08-01T00:00:00Z